Healthequity (HQY) EBITDA (2013 - 2026)

Healthequity's EBITDA history runs 14 years deep, the most recent figure standing at $103.0 million for Q2 2026.

• On a quarterly basis, EBITDA rose 23.92% year-over-year to $103.0 million in Q2 2026; TTM through Apr 2026 was $342.3 million, a 67.99% increase from a year earlier, with the FY2026 full-year figure at $322.5 million, up 98.64% from the prior year.
• EBITDA rose to $103.0 million in Q2 2026 per HQY's latest filing, from $71.1 million in the prior quarter.
• Across five years, EBITDA topped out at $103.0 million in Q2 2026 and bottomed at -$27.2 million in Q1 2022.
• The 5-year median for EBITDA is $34.9 million (2023), against an average of $38.2 million.
• Biggest YoY gain for EBITDA was 1614.21% in 2022; the steepest drop was 1617.08% in 2022.
• Year by year, EBITDA stood at $5.5 million in 2022, then surged by 457.4% to $30.9 million in 2023, then slumped by 36.47% to $19.6 million in 2024, then soared by 300.99% to $78.7 million in 2025, then soared by 30.83% to $103.0 million in 2026.
• Per Business Quant, the three latest HQY EBITDA figures stand at $103.0 million (Q2 2026), $71.1 million (Q1 2026), and $78.7 million (Q4 2025).